Almac Group, the global contract pharmaceutical development and manufacturing organization, has today, (7 June), announced its financial results for year ending 30 September 2022.
Today’s figures show the company recorded a $134 million (14.3%) rise in revenue to $1.076 billion in 2022. Pre-tax profits were recorded at $124 million, a 20% increase for the same period the previous year.
This comes as Almac also reveals today that its global workforce has now reached 7,000 people, a total growth of over 1000 employees in the last 18 months. This rise, aligned with the current capital investment program, means Almac is well on its way to delivering on the significant expansion plans that were first announced in November 2021.
Almac is at the forefront of developing, manufacturing, testing and distributing essential medicines to patients around the world. During this financial year the group was involved in the development of hundreds of life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology, gene therapy and neurology.
Alan Armstrong, Almac Group Chairman and CEO said: “Today’s announcement is a welcome continuation of growth for Almac Group, and I would like to thank all within the organization for playing their part. We are committed to reinvesting all our profits in the business, this success will play a vital part in our continued growth, expansion, and increase in our employee numbers.
“Almac is dedicated to ensuring we remain a global leader in our industry, giving our clients and ultimately patients across the world the best possible offering. We continue to play our part as a valued and trusted member of the communities in which we operate.”
About Almac Group
The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialization, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically, now employing 7,000 highly skilled personnel across 18 facilities including Europe, the USA and Asia.
The financial figures quoted in this announcement relate to the financial period 1 October 2021 to 30 September 2022. Employee numbers in this release are correct as of May 2023.